Carvedilol is an alpha-adrenergic blocker. It is available as tablets and extended-release capsules for oral use. MedsAcross supplies Carvedilol for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
1. INDICATIONS AND USAGE COREG is an alpha-/beta-adrenergic blocking agent indicated for the treatment of: mild to severe chronic heart failure left ventricular dysfunction following myocardial infarction in clinically stable patients hypertension
Source: US FDA prescribing information
COREG is a racemic mixture in which nonselective β-adrenoreceptor blocking activity is present in the S(-) enantiomer and α1-adrenergic blocking activity is present in both R(+) and S(-) enantiomers at equal potency. COREG has no intrinsic sympathomimetic activity.
Source: US FDA prescribing information
COREG should be taken with food to slow the rate of absorption and reduce the incidence of orthostatic effects. Take with food. Individualize dosage and monitor during up-titration. Heart failure: Start at 3.125 mg twice daily and increase to 6.25, 12.5, and then 25mg twice daily over intervals of at least 2 weeks. Maintain lower doses if higher doses are not tolerated. Left ventricular dysfunction following myocardial infarction. Start at 6.25 mg twice daily and increase to 12.5 mg then 25 mg twice daily after intervals of 3 to 10 days. A lower starting dose or slower titration may be used. Hypertension: Start at 6.25 mg twice daily and increase if needed for blood pressure control to 12.5 mg and then 25 mg twice daily over intervals of 1 to 2 weeks.
Source: US FDA prescribing information
COREG is contraindicated in the following conditions: Bronchial asthma or related bronchospastic conditions. Deaths from status asthmaticus have been reported following single doses of COREG. Second- or third-degree AV block. Sick sinus syndrome. Severe bradycardia (unless a permanent pacemaker is in place). Patients with cardiogenic shock or who have decompensated heart failure requiring the use of intravenous inotropic therapy. Such patients should first be weaned from intravenous therapy before initiating COREG. Patients with severe hepatic impairment.
Source: US FDA prescribing information
Acute exacerbation of coronary artery disease upon cessation of therapy: Do not abruptly discontinue. Bradycardia, hypotension, worsening heart failure/fluid retention may occur. Reduce the dose as needed. Non-allergic bronchospasm (e.g., chronic bronchitis and emphysema). Avoid β-blockers. However, if deemed necessary, use with caution and at lowest effective dose. Diabetes: May mask symptoms of hypoglycemia and alter glucose levels, monitor.
Source: US FDA prescribing information
Most common adverse events: Heart failure and left ventricular dysfunction following myocardial infarction (≤10%): Dizziness, fatigue, hypotension, diarrhea, hyperglycemia, asthenia, bradycardia, weight increase. Hypertension (≥5%): Dizziness.
Source: US FDA prescribing information
CYP P450 2D6 enzyme inhibitors may increase and rifampin may decrease carvedilol levels. Hypotensive agents (e.g., reserpine, MAO inhibitors, clonidine) may increase the risk of hypotension and/or severe bradycardia. Cyclosporine or digoxin levels may increase. Both digitalis glycosides and β-blockers slow atrioventricular conduction and decrease heart rate. Concomitant use can increase the risk of bradycardia. Amiodarone may increase carvedilol levels resulting in further slowing of the heart rate or cardiac conduction. Verapamil- or diltiazem-type calcium channel blockers may affect ECG and/or blood pressure. Insulin and oral hypoglycemics action may be enhanced.
Source: US FDA prescribing information
Store below 30°C (86°F). Protect from moisture.
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
16 presentations of Carvedilol, sorted by availability.
2 brand names across 1 markets.
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 14 September 1995 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Carvedilol in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 16 presentations of Carvedilol and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 2 brand names for Carvedilol, including Coreg, Coreg CR.
Yes. The US FDA first approved Carvedilol on 14 September 1995, according to Drugs@FDA.
No listed presentation of Carvedilol is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Carvedilol is classified under ATC code C07AG02 (Carvedilol).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.